QualityDipStocks / Health Care · Pharmaceuticals
OPKO Health OPK
Outside our quality screen, so we don’t track its dips. It’s 1% below its 52-week high.
Outside our quality screen, 7% over its Market Value. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- $1.61price +7%
- Off 52-wk high
- −1%
- Risk vs market
- Below marketbeta 0.87
52-week range at its 52-week high
Price $1.72Market Value $1.61
3 bullish · 5 bearish See why
Repriced or dip?
Near its high
The price is 1% below its 52-week high (Sep 22), but the business held up: net cash (cash minus debt) 0.0% of market cap since the high, shares outstanding more shares, each owns less, operating margin 0.0 pts.
Some numbers held up (net cash (cash minus debt) 0.0% of market cap since the high, shares outstanding more shares, each owns less, operating margin 0.0 pts), others slipped. The price is 1% below its 52-week high.
The price is 1% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for OPK: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much OPK moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves a bit less than the market, and its own price swings are 4.5× the S&P 500’s.
- Beta vs S&P 500
- 0.87
- Volatility
- 58% vs 13% SPY
- Correlation SPY
- 0.19
- Correlation QQQ
- 0.10
How it ranks
Where OPK stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 5 measures
- Free cash flow yield−10% · free cash flow vs market capLowest 4%of 1,690
- Dividends + buybacks yield3.6% · cash paid out or used to retire shares, vs market capTop 39%of 2,227
- Revenue growth, last 12 months−11% · vs the 12 months beforeLowest 3%of 2,184
- Operating margin−8.2% · of sales kept as operating profitLowest 8%of 1,549
- Return on invested capital−3.1% · profit per dollar of capitalLowest 8%of 1,001
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $1.61
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 3 of 5
Cash returnsShare count down 4.2% in a year: $47M of buybacks over 12 months.
ValuationPrice / book of 1.1×, below the 4.8× median for the 291 Health Care companies we cover.
Balance sheetDebt / equity of 0.3×, below the 0.5× median for the 161 Health Care companies we cover.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$134M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityLost $73M over the last 12 months (net income, SEC filings).
GrowthSales shrank 15% a year from FY2022 to FY2025.
ProfitabilityLoses money at the operating line: −8% operating margin over the last 12 months.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; debt load unclear or high.
All fundamentals
FCF yield -10.3% · ROE -6% · Sales −11%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −10.3%
- EV / EBITDA
- 32.5×
- Price / sales
- 2.21×
- Price / book
- 1.10×
- Market cap
- $1.3Blisted
- Enterprise value
- $1.3B
Growth
- Revenue, 12 months
- $588M
- Sales growth, 12 months
- −11.5%vs the 12 months before
- Sales growth, 3 yrs
- −15.5%/yrfrom FY2022
- Diluted EPS, 12 months
- −$0.07
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$73M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 40.8%
- Operating margin
- −8.2%
- Net margin
- −12.4%
- FCF margin
- −22.8%
- Return on equity
- −6%
- Return on invested capital
- −3%
Balance sheet
- Cash & short-term inv.
- $301M
- Total debt
- $349M
- Net cash
- −$48M
- Debt / equity
- 0.29×
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$134M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $47M3.6% of market cap
- Share count, 1 year
- −4.2%diluted shares vs a year ago
- Stock-based comp
- $11M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From OPKO Health’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.1B · Sales +4%
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield-10.3%
- Gross margin20%
- Operating margin−15%
- Return on invested capital−6%
- Return on equity−6%
- Sales growth (latest quarter vs year-ago quarter)+4%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $1.72
- 52-wk lowlowest close, 1 year$1.10−36.0%
- Market Valueavg paid since Oct 15$1.61−6.4%
- PriceMon Nov 2 close$1.72you are here
- 52-wk highhighest close, 1 year$1.73+0.6%
Momentum & 52-week range
RSI 63 · 5 days +5.5%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 4
- DateWed Nov 4, after the close
- Consensus EPS($0.07)
- Year-ago EPS$0.03
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
OPK is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on OPKO Health in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.